Cytidine 5′-Diphosphocholine (Citicoline) in Glaucoma: Rationale of Its Use, Current Evidence and Future Perspectives

International Journal of Molecular Sciences

Gloria Roberti²  Lucia Tanga²  Manuele Michelessi²  Luciano Quaranta³  Vincenzo Parisi²  Gianluca Manni¹  Francesco Oddone² 

[1] DSCMT, Università di Roma Tor Vergata, Viale Oxford 81, 00133 Rome, Italy;IRCCS-Fondazione GB Bietti, Via Livenza, 3, 00198 Rome, Italy;DSMC, Università degli studi di Brescia, USVD “Centro per lo studio del Glaucoma” P.le Spedali Civili, 1, 25123 Brescia, Italy;

关键词: citicoline;    glaucoma;    neuroprotection;    retinal ganglion cells;   

DOI  :  10.3390/ijms161226099

来源: mdpi

【 摘 要 】

Cytidine 5′-diphosphocholine or citicoline is an endogenous compound that acts in the biosynthetic pathway of phospholipids of cell membranes, particularly phosphatidylcholine, and it is able to increase neurotrasmitters levels in the central nervous system. Citicoline has shown positive effects in Parkinson’s disease and Alzheimer’s disease, as well as in amblyopia. Glaucoma is a neurodegenerative disease currently considered a disease involving ocular and visual brain structures. Neuroprotection has been proposed as a valid therapeutic option for those patients progressing despite a well-controlled intraocular pressure, the main risk factor for the progression of the disease. The aim of this review is to critically summarize the current evidence about the effect of citicoline in glaucoma.

【 授权许可】

CC BY   
© 2015 by the authors; licensee MDPI, Basel, Switzerland.